Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

188.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
79 80 Next >
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Revenue growth during what should be a disastrous patent cliff is encouraging. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
10 Stocks to Build a Dividend Portfolio With
All 10 of these stocks pay reliable and growing dividends. 
Via The Motley Fool
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,... 
Via Benzinga
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today
Via Benzinga
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities. 
Via InvestorPlace
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
Amid the strong run in the market, investors thinking about long-term goals should consider these strongly endorsed retirement stocks to buy. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors. 
Via The Motley Fool
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
3 Reasons to Buy AbbVie Stock on the Dip
A little patience with the drugmaker should pay off. 
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
What Is the Dividend Payout for AbbVie Stock?
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well. 
Via The Motley Fool
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
These are low-risk stocks with high yields. 
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
AbbVie Tracking for New Highs in 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions. 
Via MarketBeat
Topics Earnings
Exposures Financial
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher 
Via MarketBeat
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
These dividend aristocrat stocks can protect tired consumers from persistent inflation through dividends that outpace recent spikes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
79 80 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.